Alexander Pickett is the Chief Operating Officer at Juvenescence Limited, a drug development company focused on aging and longevity. Alexander is also a Principal at Mediqventures, a multi-family investment partnership and merchant bank. While at Mediqventures, he led investments into Causeway Therapeutics Ltd and Sentien Biotechnologies, Inc., supported existing investments at Portage Biotech Inc. and Biohaven Pharma, and helped found SalvaRx Limited, a cancer-immunotherapy focused drug development company.
Prior to joining Mediqventures, he was an Associate at Flatley Venture Capital, a cystic fibrosis focused investment arm of a family office, where he was responsible for investment analysis and scientific due diligence. While there, he also supported Flatley Discovery Lab's business development efforts. Alexander co-founded Real Life Sciences, a start-up focused on using software-based patient-engagement solutions in order to improve patient recruitment to clinical trials.
Prior to joining Flatley Venture Capital, Alexander graduated from Harvard College with an A.B. in Molecular and Cellular Biology, where he was a Microbial Studies Initiative Undergraduate Fellow and an International Genetically Engineered Machines Competition Team Member.